AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00283556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Camptosar, CPT-11)
Description: Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.
Study NCT01841632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem
Study NCT00723684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EEG Neurofeedback
Description: The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects.
Study NCT00723684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-Neurofeedback
Description: The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
Study NCT01273441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Study NCT01273441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study NCT02005055 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical excision with adjuvant high-dose-rate brachytherapy
Description: The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
Study NCT00318461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg for s.c. (under the skin) injection
Study NCT03546205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
Study NCT02577393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
Study NCT02577393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
Study NCT02577393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mLDG
Description: mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Description: 280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
Study NCT00562315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FACBC
Description: Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
Study NCT00562315 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ProstaScinct
Description: ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
Study NCT03381833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LJPC-401
Description: subcutaneous injection, up to 20 mg per week from week 26 to 52
Study NCT03381833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LJPC-401
Description: subcutaneous injection, up to 20 mg per week from week 1 to 52
Study NCT02688322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Description: 2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
Study NCT02642588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy gel
Description: energy gel: gelatinous edible containing carbohydrates typically used during endurance races
Study NCT04465201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP with Smart Assist (Circulatory Support System)
Description: Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
Study NCT00053898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg/day and placebo for 5 years
Study NCT00053898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg/day and placebo for 5 years
Study NCT00053898 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Adjuvant radiation therapy
Study NCT00053898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Adjuvant radiation therapy
Study NCT05429775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: single dose of 2 mg oral suspension formulation administered orally under fasting conditions
Study NCT03870958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GIC sealant (GC Fuji TRIAGE®)
Description: Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
Study NCT03870958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Children allocated to this group will receive the same dietary advices and brushing instructions.
Study NCT02995369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DryShield
Description: DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone releasing hormone [LHRH] agonist
Description: Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
Study NCT02995369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cotton rolls
Description: Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
Study NCT00004054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
Study NCT00004054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: To keep international normalized ratio (INR) > 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
Study NCT01138878 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
Study NCT01138878 — intervention group
Intervention type: OTHER
Intervention: Focus Group Discussion
Description: FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
Study NCT02521155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safeguard Your Smile an oral health literacy intervention
Description: Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month.
Study NCT01634932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular iron
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
Study NCT01634932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron biofortified millet
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
Study NCT01634932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-harvest iron-fortifed millet
Description: Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
Study NCT01666223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
Study NCT01666223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Description: 1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
Study NCT01666223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Description: 100 ml saline
Study NCT01666223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
Description: Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestrone vaginal insert
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestrone vaginal insert
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone in oil
Description: 50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
Study NCT00802360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
Study NCT01418495 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT01418495 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01911858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol Paste
Study NCT01186393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
Study NCT01186393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index
Description: Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
Study NCT01186393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Glycemic Index
Description: Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
Study NCT03425708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg Febuxostat
Description: Participants take 20mg febuxostat pill once a day for at least six months.
Study NCT03425708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg Febuxostat
Description: Participants take 40mg febuxostat pill once a day for at least six months.
Study NCT01461681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptom Management Service for Heart failure
Description: The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
Study NCT00271388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous current to the vestibular nerve
Description: Delivery of randomly oscillating low level current
Study NCT01413958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
Study NCT01413958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
Study NCT01413958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
Study NCT01413958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
Study NCT01614964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ-13 Treatment
Description: Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
Study NCT01614964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem Treatment
Description: Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
Study NCT03030287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-305B83
Description: intravenous (in the vein) infusion
Study NCT03030287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered intravenously
Study NCT03689192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARG1-18,19,20
Description: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
Study NCT01332448 — intervention group
Intervention type: DRUG
Intervention: Orlistat 120
Description: Orlistat 120mg tid
Study NCT01332448 — intervention group
Intervention type: DRUG
Intervention: Orlistat 60
Description: Orlistat 60mg tid